Transcatheter arterial chemoembolization of liver tumors: Effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency

被引:83
作者
Geschwind, JFH
Ramsey, DE
Cleffken, B
van der Wal, BCH
Kobeiter, H
Juluru, K
Hartnell, GG
Choti, MA
机构
[1] Johns Hopkins Univ Hosp, Dept Radiol, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Radiol, Russell H Morgan Dept Radiol, Baltimore, MD 21287 USA
[3] Johns Hopkins Univ, Sch Med, Dept Radiol, Russell H Morgan Dept Surg, Baltimore, MD 21287 USA
[4] Erasme Univ Hosp, Dept Surg, Rotterdam, Netherlands
[5] Baystate Med Ctr, Dept Cardiovasc & Intervent Radiol, Springfield, MA 01199 USA
关键词
liver neoplasms; chemotherapeutic embolization; arteries; blood supply; embolic material; angiography;
D O I
10.1007/s00270-002-2524-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to determine whether transcatheter arterial chemioembolization (TACE) protocol affects the total volume of chemotherapy injected into the liver as well as subsequent arterial patency. A total of 160 patients with primary or secondary liver cancer were treated with 3 different chemoembolization protocols at a single institution. Data were analyzed retrospectively. Group 1 (n = 36) consisted of slurry of chemotherapy, oil and polyvinyl alcohol particles (PVA), group 2 (n = 91), chemotherapy and oil followed by PVA, and group 3 (n = 33), chemotherapy and oil followed by Gelfoam pledgets. The total volume of chemotherapy injected into the liver was recorded. Arterial patency was determined during subsequent chemoembolizations. The mean percentage of total intended chemotherapy dose administered was 54.6% for group 1, 75.3% for group 2, and 80.6% for group 3. Arterial patency at follow-up angiography was 56% for group 1, 74% for group 2, and 81% for group 3. The slurry protocol (group 1) significantly reduced arterial patency and injectable volume of chemotherapy during TACE.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 31 条
[1]  
Bayraktar Y, 1996, HEPATO-GASTROENTEROL, V43, P681
[2]   HEPATIC-ARTERY CHEMOEMBOLIZATION OR EMBOLIZATION FOR PRIMARY AND METASTATIC LIVER-TUMORS - POSTTREATMENT MANAGEMENT AND COMPLICATIONS [J].
BERGER, DH ;
CARRASCO, CH ;
HOHN, DC ;
CURLEY, SA .
JOURNAL OF SURGICAL ONCOLOGY, 1995, 60 (02) :116-121
[3]   Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma [J].
Bronowicki, JP ;
Boudjema, K ;
Chone, L ;
Nisand, G ;
Bazin, C ;
Pflumio, F ;
Uhl, G ;
Wenger, JJ ;
Jaeck, D ;
Boissel, P ;
Bigard, MA ;
Gaucher, P ;
Vetter, D ;
Doffoel, M .
JOURNAL OF HEPATOLOGY, 1996, 24 (03) :293-300
[4]   Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:: Results of a randomized, controlled trial in a single institution [J].
Bruix, J ;
Llovet, JM ;
Castells, A ;
Montañá, X ;
Brú, C ;
Ayuso, MD ;
Vilana, R ;
Rodés, J .
HEPATOLOGY, 1998, 27 (06) :1578-1583
[5]  
Chung JW, 1998, HEPATO-GASTROENTEROL, V45, P1236
[6]  
Clouse M E, 1993, J Vasc Interv Radiol, V4, P717, DOI 10.1016/S1051-0443(93)71956-9
[7]   Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors [J].
Drougas, JG ;
Anthony, LB ;
Blair, TK ;
Lopez, RR ;
Wright, JK ;
Chapman, WC ;
Webb, L ;
Mazer, M ;
Meranze, S ;
Pinson, CW .
AMERICAN JOURNAL OF SURGERY, 1998, 175 (05) :408-412
[8]  
GESCHWIND JFH, 2002, IN PRESS AM J CLIN O
[9]  
GUILLAIS L, 1991, Journal de Pharmacie Clinique, V10, P241
[10]   UNRESECTABLE HEPATOCELLULAR-CARCINOMA - ANALYSIS OF PROGNOSTIC FACTORS IN TRANSCATHETER MANAGEMENT [J].
HATANAKA, Y ;
YAMASHITA, Y ;
TAKAHASHI, M ;
KOGA, Y ;
SAITO, R ;
NAKASHIMA, K ;
URATA, J ;
MIYAO, M .
RADIOLOGY, 1995, 195 (03) :747-752